Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.

Por Piscitelli, S C, Figg, W D, Hahn, B, Kelly, G, Thomas, S, Walker, R E
Publicado em 1997

Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor

Por Horti, J, Dixon, S C, Logothetis, C J, Guo, Y, Reed, E, Figg, W D
Publicado em 1999

Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100

Por Smith, N F, Baker, S D, Gonzalez, F J, Harris, J W, Figg, W D, Sparreboom, A
Publicado em 2008

Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.

Por Walsh, T J, Whitcomb, P, Piscitelli, S, Figg, W D, Hill, S, Chanock, S J, Jarosinski, P, Gupta, R, Pizzo, P A
Publicado em 1997

Angiogenesis in Spontaneous Tumors and Implications for Comparative Tumor Biology

Por Benazzi, C., Al-Dissi, A., Chau, C. H., Figg, W. D., Sarli, G., de Oliveira, J. T., Gärtner, F.
Publicado em 2014

Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.

Por Bergan, R. C., Walls, R. G., Figg, W. D., Dawson, N. A., Headlee, D., Tompkins, A., Steinberg, S. M., Reed, E.
Publicado em 1997